In this post in the Hill’s “Congress Blog,” John Castellani, president and CEO of Pharmaceutical Research and Manufacturers of America, reports on how biopharmaceutical exports benefit the U.S. economy and global health, writing, “Leadership is needed to help keep U.S. biopharmaceutical research companies competitive in the global export market.” He continues, “According to the Administration, if we increased exports by just five percent, we would create hundreds of thousands of new U.S. jobs. … Among the ways that they can advance this effort is by knocking down foreign barriers and promoting strong intellectual property (IP) protections that allow biopharmaceutical companies to bring their medicines into other markets and, importantly, to the patients who need them.”
Access to Health Services
In Swaziland, where a “deepening financial crisis is taking a toll on service delivery, and the country is experiencing an unprecedented number of protests over issues such as school closures and a lack of HIV treatment,” “[a] new wave of HIV activism is rising … as people living with HIV take to the streets in protest, many for the first time in their lives, over continued shortages of antiretroviral (ARV) treatment,” PlusNews reports.
“We welcome the Obama administration’s announcement of a farsighted effort to treat millions more [people living with HIV] abroad, especially in sub-Saharan Africa,” a New York Times editorial writes. “The administration expects that the expanded treatments can be paid for with existing resources, by pushing for greater efficiencies and more financing from recipient nations. But if that effort stalls, the administration should re-evaluate quickly whether to ask Congress for money,” the editorial states.
In this post in the Hill’s “Congress Blog,” Kaitlin Christenson, the coalition director of the Global Health Technologies Coalition; Jim Connolly, president and CEO of Aeras; and Mel Spigelman, president and CEO of the TB Alliance, respond to a recently released G-FINDER report that shows “overall global investment in the research and development (R&D) of [new global health technologies] has declined for the first time since 2007, when the tracking of such funding began,” writing, “This decline is especially troubling given that there are more than 100 products in [the Product Development Partnerships’ (PDPs)] pipelines.”
Unexplained Kidney Disease Affecting Rural Workers Across Central America, PRI’s ‘The World’ Reports
PRI’s “The World” reports on an epidemic of an unexplained kidney disease that is affecting rural workers across Central America, writing, “[I]t’s the second biggest cause of death among men in El Salvador, and in Nicaragua it’s a bigger killer of men than HIV and diabetes combined,” and “the latest theory is that the victims are literally working themselves to death.” According to the news service, “El Salvador’s health minister recently called on the international community for help,” stating that “the epidemic is ‘wasting away our populations.'”
“The Central African Republic (CAR) is in the grips of a chronic medical emergency, according to a report released today by the international medical humanitarian organization Doctors Without Borders/Medecins Sans Frontieres (MSF),” an MSF press release states. “Four mortality studies carried out by MSF over the past 18 months reveal crude mortality rates in some regions of CAR at three times the emergency threshold of one death per 10,000 people per day, which, according to the World Health Organization, is considered a humanitarian crisis,” the press release adds (12/13).
“Global HIV/AIDS prevention and treatment efforts are missing a major opportunity to significantly improve health conditions in poor countries by simply adding low-cost care for the many other chronic and disabling diseases routinely afflicting and often killing these same patients, according to a panel of disease experts who spoke at…
In this post in Huffington Post’s “Impact” blog, Orin Levine of the Department of International Health at Johns Hopkins Bloomberg School of Public Health and executive director of the International Vaccine Access Center (IVAC) recounts recent progress in expanding vaccine access to the world’s poor, writing, “From rolling out the first diarrhea vaccines in Africa, to doubling the number of low-income countries approved for vaccines against pneumonia, to announcing they will now assist countries [to] introduce vaccines for that prevent cervical cancer, the GAVI Alliance and its partners are tearing down the barriers to vaccine access that have historically divided rich from poor on our planet. To appreciate how far we’ve come you need to remember where we started.”
Science examines recent successes in clinical trials in the HIV prevention field, limitations to mathematical models resulting from these trials, and funding issues facing campaigns to ramp up HIV prevention interventions. “[M]odels now suggest that combining [prevention strategies] might virtually stop HIV’s spread,” but “there’s a vast difference between a study having success and thwarting HIV in the real world,” according to Science. “Models only point out routes to ending AIDS, and many will surely differ,” the magazine writes, concluding, “But for the first time since AIDS surfaced 31 years ago, many researchers believe the destination itself is no longer a mirage” (Cohen, 12/9).
“The Millennium Challenge Corporation (MCC), through its partnership with the Millennium Challenge Account-Lesotho, is helping Lesotho address key challenges in its health sector through a $122 million investment in health infrastructure and health systems,” IIP Digital reports. “More than 720,000 Basotho are expected to benefit from the MCC health project over the next 20 years,” the news service writes.